{"url":"https://lda.senate.gov/api/v1/filings/868e323e-b8f7-42e5-a3d2-ce8aedb51607/","filing_uuid":"868e323e-b8f7-42e5-a3d2-ce8aedb51607","filing_type":"4T","filing_type_display":"4th Quarter - Termination","filing_year":2019,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/868e323e-b8f7-42e5-a3d2-ce8aedb51607/print/","filing_document_content_type":"text/html","income":"10000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Paul J. Reagan, Sr. Vice President & Director","dt_posted":"2020-01-21T14:37:59.027000-05:00","termination_date":"2019-12-31","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2001 K Street, NW; Suite 400","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":24486,"url":"https://lda.senate.gov/api/v1/registrants/24486/","house_registrant_id":33788,"name":"MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP)","description":"​Public Affairs Government Relations Services","address_1":"888 16th Street, N.W.; Suite 500","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"RYAN M. BERNSTEIN","contact_telephone":"+1 202-857-2909","dt_updated":"2026-07-29T10:26:26.735165-04:00"},"client":{"id":132319,"url":"https://lda.senate.gov/api/v1/clients/132319/","client_id":1004125,"name":"INOVIO PHARMACEUTICALS","general_description":"Pharmaceuticals","client_government_entity":false,"client_self_select":null,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65471,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"WASINGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}